Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Retained Earnings (2022 - 2025)

Historic Retained Earnings for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$46.5 million.

  • 60 Degrees Pharmaceuticals' Retained Earnings fell 2071.47% to -$46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.5 million, marking a year-over-year decrease of 2071.47%. This contributed to the annual value of -$40.5 million for FY2024, which is 2439.2% down from last year.
  • 60 Degrees Pharmaceuticals' Retained Earnings amounted to -$46.5 million in Q3 2025, which was down 2071.47% from -$44.1 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Retained Earnings' 5-year high stood at -$28.8 million during Q4 2022, with a 5-year trough of -$46.5 million in Q3 2025.
  • For the 4-year period, 60 Degrees Pharmaceuticals' Retained Earnings averaged around -$37.0 million, with its median value being -$36.3 million (2024).
  • In the last 5 years, 60 Degrees Pharmaceuticals' Retained Earnings tumbled by 452.17% in 2024 and then plummeted by 3189.43% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Retained Earnings stood at -$28.8 million in 2022, then dropped by 13.07% to -$32.6 million in 2023, then fell by 24.39% to -$40.5 million in 2024, then decreased by 14.62% to -$46.5 million in 2025.
  • Its Retained Earnings was -$46.5 million in Q3 2025, compared to -$44.1 million in Q2 2025 and -$42.4 million in Q1 2025.